Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients

P. Klepstad, P. C. Borchgrevink, O. Dale, K. Zahlsen, T. Aamo, Peter Fayers, B. Fougner, S. Kaasa

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

The clinical importance of routine drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. We measured morphine, M6G and M3G serum concentrations in cancer pain patients receiving oral ( n = 263, median dose 80 mg/24 hours) or subcutaneous (sc) ( n = 35, median dose 110 mg/24 hours) morphine. Regression analyses were performed to investigate if serum concentrations of morphine, M3G and M6G predicted pain intensity ( Brief Pain Inventory), health-related quality-of-life variables (EORTC QLQ-C30) and cognitive function ( Mini-Mental Score). Serum concentrations were also compared in patients categorized as morphine 'treatment successes' and 'treatment failures'.

We observed that serum concentrations of morphine, M6G or M3G did not predict pain intensity, cognitive function, nausea or tiredness. 'Treatment failures' caused by nausea, tiredness, cognitive failure or constipation did not have statistically significant different morphine, M6G and M3G serum concentrations than patients classified as ' treatment successes`.

In conclusion, this study did not observe any concentration - effect relationships of morphine, M3G or M6G with pain intensity, nausea, constipation, tiredness or cognitive failure in blood samples obtained during routine clinical drug monitoring in cancer patients. This result suggests that therapeutic drug monitoring as a routine tool during chronic morphine treatment has limited value for clinical decision making.

Original languageEnglish
Pages (from-to)679-687
Number of pages8
JournalPalliative Medicine
Volume17
DOIs
Publication statusPublished - 2003

Keywords

  • cancer
  • drug monitoring
  • morphine
  • morphine-3-glucuronide
  • morphine-6-glucuronide
  • PLASMA-CONCENTRATIONS
  • CEREBROSPINAL-FLUID
  • HOSPICE INPATIENTS
  • RECEIVING MORPHINE
  • PALLIATIVE CARE
  • PAIN
  • ANALGESIA
  • ANTINOCICEPTION
  • QUESTIONNAIRE
  • GLUCURONIDES

Cite this

Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. / Klepstad, P.; Borchgrevink, P. C.; Dale, O.; Zahlsen, K.; Aamo, T.; Fayers, Peter; Fougner, B.; Kaasa, S.

In: Palliative Medicine, Vol. 17, 2003, p. 679-687.

Research output: Contribution to journalArticle

Klepstad, P. ; Borchgrevink, P. C. ; Dale, O. ; Zahlsen, K. ; Aamo, T. ; Fayers, Peter ; Fougner, B. ; Kaasa, S. / Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients. In: Palliative Medicine. 2003 ; Vol. 17. pp. 679-687.
@article{5fbcd08d30324208bcdf244d435b39f2,
title = "Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients",
abstract = "The clinical importance of routine drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. We measured morphine, M6G and M3G serum concentrations in cancer pain patients receiving oral ( n = 263, median dose 80 mg/24 hours) or subcutaneous (sc) ( n = 35, median dose 110 mg/24 hours) morphine. Regression analyses were performed to investigate if serum concentrations of morphine, M3G and M6G predicted pain intensity ( Brief Pain Inventory), health-related quality-of-life variables (EORTC QLQ-C30) and cognitive function ( Mini-Mental Score). Serum concentrations were also compared in patients categorized as morphine 'treatment successes' and 'treatment failures'.We observed that serum concentrations of morphine, M6G or M3G did not predict pain intensity, cognitive function, nausea or tiredness. 'Treatment failures' caused by nausea, tiredness, cognitive failure or constipation did not have statistically significant different morphine, M6G and M3G serum concentrations than patients classified as ' treatment successes`.In conclusion, this study did not observe any concentration - effect relationships of morphine, M3G or M6G with pain intensity, nausea, constipation, tiredness or cognitive failure in blood samples obtained during routine clinical drug monitoring in cancer patients. This result suggests that therapeutic drug monitoring as a routine tool during chronic morphine treatment has limited value for clinical decision making.",
keywords = "cancer, drug monitoring, morphine, morphine-3-glucuronide, morphine-6-glucuronide, PLASMA-CONCENTRATIONS, CEREBROSPINAL-FLUID, HOSPICE INPATIENTS, RECEIVING MORPHINE, PALLIATIVE CARE, PAIN, ANALGESIA, ANTINOCICEPTION, QUESTIONNAIRE, GLUCURONIDES",
author = "P. Klepstad and Borchgrevink, {P. C.} and O. Dale and K. Zahlsen and T. Aamo and Peter Fayers and B. Fougner and S. Kaasa",
year = "2003",
doi = "10.1191/0269216303pm835oa",
language = "English",
volume = "17",
pages = "679--687",
journal = "Palliative Medicine",
issn = "0269-2163",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Routine drug monitoring of serum concentrations of morphine, morphine-3-glucuronide and morphine-6-glucuronide do not predict clinical observations in cancer patients

AU - Klepstad, P.

AU - Borchgrevink, P. C.

AU - Dale, O.

AU - Zahlsen, K.

AU - Aamo, T.

AU - Fayers, Peter

AU - Fougner, B.

AU - Kaasa, S.

PY - 2003

Y1 - 2003

N2 - The clinical importance of routine drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. We measured morphine, M6G and M3G serum concentrations in cancer pain patients receiving oral ( n = 263, median dose 80 mg/24 hours) or subcutaneous (sc) ( n = 35, median dose 110 mg/24 hours) morphine. Regression analyses were performed to investigate if serum concentrations of morphine, M3G and M6G predicted pain intensity ( Brief Pain Inventory), health-related quality-of-life variables (EORTC QLQ-C30) and cognitive function ( Mini-Mental Score). Serum concentrations were also compared in patients categorized as morphine 'treatment successes' and 'treatment failures'.We observed that serum concentrations of morphine, M6G or M3G did not predict pain intensity, cognitive function, nausea or tiredness. 'Treatment failures' caused by nausea, tiredness, cognitive failure or constipation did not have statistically significant different morphine, M6G and M3G serum concentrations than patients classified as ' treatment successes`.In conclusion, this study did not observe any concentration - effect relationships of morphine, M3G or M6G with pain intensity, nausea, constipation, tiredness or cognitive failure in blood samples obtained during routine clinical drug monitoring in cancer patients. This result suggests that therapeutic drug monitoring as a routine tool during chronic morphine treatment has limited value for clinical decision making.

AB - The clinical importance of routine drug monitoring of serum concentrations of morphine, morphine-6-glucuronide (M6G) and morphine-3-glucuronide (M3G) during chronic morphine therapy is not established. We measured morphine, M6G and M3G serum concentrations in cancer pain patients receiving oral ( n = 263, median dose 80 mg/24 hours) or subcutaneous (sc) ( n = 35, median dose 110 mg/24 hours) morphine. Regression analyses were performed to investigate if serum concentrations of morphine, M3G and M6G predicted pain intensity ( Brief Pain Inventory), health-related quality-of-life variables (EORTC QLQ-C30) and cognitive function ( Mini-Mental Score). Serum concentrations were also compared in patients categorized as morphine 'treatment successes' and 'treatment failures'.We observed that serum concentrations of morphine, M6G or M3G did not predict pain intensity, cognitive function, nausea or tiredness. 'Treatment failures' caused by nausea, tiredness, cognitive failure or constipation did not have statistically significant different morphine, M6G and M3G serum concentrations than patients classified as ' treatment successes`.In conclusion, this study did not observe any concentration - effect relationships of morphine, M3G or M6G with pain intensity, nausea, constipation, tiredness or cognitive failure in blood samples obtained during routine clinical drug monitoring in cancer patients. This result suggests that therapeutic drug monitoring as a routine tool during chronic morphine treatment has limited value for clinical decision making.

KW - cancer

KW - drug monitoring

KW - morphine

KW - morphine-3-glucuronide

KW - morphine-6-glucuronide

KW - PLASMA-CONCENTRATIONS

KW - CEREBROSPINAL-FLUID

KW - HOSPICE INPATIENTS

KW - RECEIVING MORPHINE

KW - PALLIATIVE CARE

KW - PAIN

KW - ANALGESIA

KW - ANTINOCICEPTION

KW - QUESTIONNAIRE

KW - GLUCURONIDES

U2 - 10.1191/0269216303pm835oa

DO - 10.1191/0269216303pm835oa

M3 - Article

VL - 17

SP - 679

EP - 687

JO - Palliative Medicine

JF - Palliative Medicine

SN - 0269-2163

ER -